Get trade alerts

Guggenheim Rates BillionToOne (BLLN) buy, $125 Price Target

Guggenheim maintains its buy rating for BillionToOne with a $125 price target, a 4.18% upside from the current price.

By · Published · Updated

Reviewed by automated data checks against the source data. How we make and check alerts

Guggenheim rated BillionToOne, Inc. ($BLLN) "buy" with a $125 price target on June 29, 2026.

Since the rating, $BLLN is up 2.5% after 1 week, up 10.1% after 1 month and down 18.5% to date (from the $120.40 close on Jun 29, 2026).

BLLN BillionToOne, Inc.
$98.12 +9.89% year to date
Daily close · Oct 16, 2026

Key Points

  • On June 29, 2026, Guggenheim reiterated its buy rating for BillionToOne, Inc. (BLLN) with a price target of $125.
  • Guggenheim's $125 price target implies 4.18% upside from BillionToOne, Inc.'s ($BLLN) current $119.98 share price.
  • BillionToOne shares traded near $119.98 on Wednesday, with a market cap of about $5.52 billion and a forward P/E of 116.5.
  • Emerald Advisers, LLC increased its holdings in BillionToOne by 50,613 shares, now holding 239,562 shares valued at $18.91 million.

Get $BLLN trade alerts by text

We text you when insiders, Congress or big funds trade $BLLN. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated BillionToOne, Inc. alert may contain errors. Disclosures

Guggenheim reiterated its buy rating on BillionToOne, Inc. (NASDAQGS: BLLN) on June 29, 2026, setting a price target of $125. The analyst, Subbu Nambi, continues to view the stock favorably.

Other Institutional Activity in BillionToOne

Emerald Advisers, LLC grew its holdings by 50,613 shares, ending with 239,562 shares worth about $18.91 million. Ameriprise Financial Inc added 97,762 shares, now holding 220,035 shares valued at $17.37 million. Next Century Growth Investors LLC increased its stake by 53,905 shares to 90,564 shares, valued at $7.15 million. Meanwhile, Lord, Abbett & Co. LLC slightly trimmed its position by 2,019 shares, maintaining 44,289 shares worth $3.50 million.

BillionToOne, Inc. Stock Up 16.8%

Shares of NasdaqGS:BLLN traded near $119.98 on Wednesday. BillionToOne, Inc. has a market cap of about $5.52 billion and a P/E ratio of 222.2. Its forward P/E is 116.5, and the stock has a beta of 1.3. The 52-week low is $61.96, and the high is $138.70, with moving averages of $92.58 (50-day) and $89.92 (200-day). The company maintains a strong liquidity position with a current ratio of 10.92 and a quick ratio of 10.48.

12-month forecast

$BLLN price target

BillionToOne, Inc. daily closes and this analyst's $125 target. Not advice.

Recent Earnings

BillionToOne reported revenue of approximately $354.54 million, showing a growth rate of 83.8%. The company achieved a net margin of 7% and a return on equity of 8.7%. Earnings per share stood at $0.54. The next earnings report is expected on August 5, 2026.

Earnings drift grade

Outlook vs expectations on the last report — not price action.

D+ 45/100

Reported May 6, 2026

  1. Forward outlook

    2 target cuts vs 0 raises.

  2. EPS & revenue

    EPS beat estimates by 598.2%. Revenue beat estimates by 9.7%.

  3. Profit surprise

    EBITDA beat sharply. Operating income beat sharply.

  4. Pre-earnings setup

    Bar was high, analysts already very bullish.

  5. Analyst signal

    2 target cuts.

  6. Earnings quality

    Gross margin up 8.6 points. Operating margin up 20.4 points.

Earnings Call Summary

BillionToOne delivered a standout quarter with 108.4 million dollars in revenue, up 84 percent year over year, while achieving 16 percent operating profit margin and 24 percent adjusted EBITDA margin. Prenatal revenue hit 97.7 million dollars, up 72 percent, and oncology revenue nearly quintupled to 10.7 million dollars. The company launched Unity Confirm, a first noninvasive fetal cell confirmation test, and signed landmark payer contracts with Anthem and United, now covering 300 million lives. Gross margins expanded to 73 percent, up 9 percentage points year over year, driven by higher pricing per test and lower production costs despite growing oncology volume.

Guidance Management raised 2026 total revenue guidance to 445 to 465 million dollars, up 20 million dollars from prior March guidance. They expect 48 to 52 percent growth versus 2025 results. The raise reflects strong Q1 performance and new payer contracts expected to boost pricing per test over the rest of the year.

Negative report. Results or guidance disappointed and expectations are likely to move lower.

Analysts Set New Price Targets

On June 29, 2026, Guggenheim reiterated its buy rating with a $125 price target. Previously, JP Morgan and BTIG maintained their buy ratings with targets of $125 and $130, respectively, on May 7, 2026. Overall, the consensus among seven analysts is a buy rating with a mean price target of $117.71.

About BillionToOne, Inc.

BillionToOne, Inc. is a healthcare company based in Menlo Park, California. It specializes in precision diagnostics, using molecular counting technology to enhance disease detection. Its products include UNITY Complete, a prenatal screening test, and Northstar Select, a liquid biopsy test for cancer mutation detection. The company was founded in 2016 and is led by CEO Dr. Oguzhan Atay.

Bottom Line

Guggenheim's reiterated buy rating and $125 price target suggest continued confidence in BillionToOne's growth prospects. Investors keep a close watch on such analyst updates to gauge market sentiment. As always with 13F filings, remember these insights reflect past positions and may not indicate current holdings.

Related Filing Alerts

Source: Guggenheim's rating change on $BLLN (Jun 29, 2026). Written by software, not financial advice. How we make alerts

Get $BLLN trade alerts by text